ABL001E
Total Payments
$253,145
Transactions
19
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $105,045 | 9 | 0 |
| 2019 | $139,392 | 7 | 0 |
| 2018 | $8,709 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $253,145 | 19 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PH2 MULTI CENTER OPEN LABEL RANDOMIZED STUDY IN CML CP PATIENTS PREVIOUSLY TREATED WITH IMATINIB AND NOT ACHIEVED DMR ASCIMINIB IMATINIB VS CONTINUED IMATINIB VS SWITCH TO NILOTINIB | Novartis Pharmaceuticals Corporation | $253,145 | 0 |
Top Doctors Receiving Payments for ABL001E
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Baltimore, MD | $253,145 | 19 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $253,145
Product Information
- Type Drug
- Total Payments $253,145
- Total Doctors 0
- Transactions 19
About ABL001E
ABL001E is a drug associated with $253,145 in payments to 0 healthcare providers, recorded across 19 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2018 to 2020. In 2020, $105,045 was paid across 9 transactions to 0 doctors.
The most common payment nature for ABL001E is "Unspecified" ($253,145, 100.0% of total).
ABL001E is associated with 1 research study, including "PH2 MULTI CENTER OPEN LABEL RANDOMIZED STUDY IN CML CP PATIENTS PREVIOUSLY TREATED WITH IMATINIB AND NOT ACHIEVED DMR ASCIMINIB IMATINIB VS CONTINUED IMATINIB VS SWITCH TO NILOTINIB" ($253,145).